Standardized pine bark extract (SPBE), also known as French maritime pine bark extract per its source of the Maritime pine (Pinus pinaster Aiton), offers anti-aging benefits that encompass structure, beauty, and function.
A diverse array of clinical research backs the use of this supplement, with data showing it supports the health of tissues and organs ranging from bones and skin to the arterials and the brain. More than 400 PubMed indexed studies exist on the topic of SPBE, and include positive findings in the realm of osteoarthritis, cognitive function, attention-deficit hyperactivity disorder, autoimmune disease, allergies, and even sexual health and function.
Several clinical studies support the use of SPBE for metabolic dysfunction, including dysglycemia, dyslipidemia, hypertension, and their complications. SPBE has active constituents that include procyanidins, bioflavonoids, and organic acids which collectively provide strong antioxidant action, and can impact many metabolic and age-related issues simultaneously. With research, interest has only grown as the mechanisms and physiological effects of SPBE are further understood.
Diabetes. Many studies have shown a positive impact of SPBE on diabetes and its complications. SPBE supports the reduction of blood glucose levels and its uptake and utilization within the cells., SPBE has been shown to inhibit the formation of advanced glycation end products (AGEs), which play a role in the development of diabetes-related complications such as retinopathy, nephropathy, neuropathy, and cardiovascular disease.
In patient with type 2 diabetes, supplementation with SPBE at a dosage of 100 mg daily was shown to significantly lower plasma glucose levels compared to placebo, also improving endothelial function. A second, open, controlled study in type 2 diabetics investigated the impact of dosage, as 100 mg of SPBE is on the lower end of that typically used for chronic conditions. In this study, dosages of 50, 100, 200, and 300 mg/day were progressively used for a period of 3 weeks each (having no wash-out period between them). Fasting glucose was reduced dose-dependently until reaching a dosage of 200 mg/day, beyond which no further improvements were seen. However, even at 50 mg/day a significant reduction in post-prandial glucose level was seen (decreasing from 224.7 ± 19.1 mg/dL to 201.1 ± 38 mg/dL), suggesting an increased cellular utilization of glucose at low dosages as well. By the end of the study, HbA1c levels had been reduced from 8.02 ± 1.04% to 7.37 ± 1.09%, the change becoming significant after completing three weeks at 200 mg/day. Insulin levels were not altered throughout the 12-week study.
The antioxidant effects of SPBE have been shown in humans and/or animal models to support the reduction of diabetic complications related to retinal health and vision,, renal function,, diabetic ulcers, and nerve function.
Dyslipidemia. Cholesterol balance also may be improved with routine oral supplementation of SPBE. In numerous human studies, supplementation with SPBE was shown to significantly lower total cholesterol and/or low-density lipoprotein (LDL) cholesterol, while high-density lipoprotein (HDL) cholesterol was either unaffected or increased. The effects on cholesterol, as well as the reduction of cholesterol accumulation in atherosclerotic plaques, are proposed to be mediated through toll-like receptor 4 and nuclear factor-kappaB (NF–κB) pathways.,, Doses ranging from 120 mg to 360 mg daily were shown to have this cholesterol-reducing effect, along with other health benefits.
In patients with mildly impaired cholesterol metabolism (having a primary complaint of erectile dysfunction), after three months of taking 120 mg of SPBE daily, total cholesterol decreased from 209 to 192 mg/dL and LDL cholesterol decreased from 133 to 107 mg/dL. Plasma antioxidant activity and erectile function were simultaneously significantly improved. In another study, at a dosage of 150 mg daily, significant decreases in LDL cholesterol and increases in HDL cholesterol were seen in the majority of subjects after six weeks, along with a significant increase in antioxidant capacity. Finally, patients with chronic venous insufficiency (CVI) who took 360 mg of SPBE daily not only experienced significant improvements in their CVI symptom scores, but also had improved cholesterol levels, with total cholesterol decreasing from 264 to 212 mg/dL and LDL cholesterol decreasing from 169 to 147 mg/dL after a period of only four weeks.
Hypertension. As a monotherapy and as an adjunctive to pharmaceutical treatment, SPBE has been shown clinically to lower blood pressure and improve endothelial function. Antioxidants play an important role in nitric oxide (NO) production and release from endothelial cells, promoting vasodilation. In humans, SPBE has been shown to improve forearm blood flow via the increase in NO production. Supplementation of SPBE also significantly improved flow-mediated dilation (as well as markers of oxidative stress) in patients with coronary artery disease and individuals with borderline metabolic syndrome. The benefits seen with supplementation of SPBE on blood vessel function also have been shown to translate to tinnitus and Meniere’s disease.,
In mildly hypertensive patients, supplementation of 200 mg of SPBE daily led to a significant improvement in systolic blood pressure (SBP), with the SBP decreasing from 140 mmHg at baseline to 133 mmHg at eight weeks compared to only 139 mmHg with placebo. Trends of improvement in diastolic blood pressure (DBP) were also seen. In the subset of individuals with more severe hypertension, a more dramatic effect was seen, with SBP being reduced from 150 mmHg to 134 mmHg.
Multiple studies have shown that supplementation with SPBE significantly reduces the need for anti-hypertensive medications, with stable blood pressures being maintained., In hypertensive patients with early signs of renal compromise, as an adjunctive support to medication, SPBE supplementation significantly decreased DBP and improved markers of kidney function as well. SPBE also has been shown to reduce markers of edema, a potential side effect associated with anti-hypertensive medications.
Abdominal adipose. SPBE also supports a healthy balance of brown and white adipose tissue, and related to this, a healthy waistline. SPBE has been shown to induce the browning of white adipose, increasing levels of brown adipose tissue which is protective against obesity and diabetes. In mice, treatment with the extract also reversed body weight and increases in white adipose tissue caused by high-fat and high-cholesterol diet feeding.31 Other studies have shown that SPBE inhibits adipogenesis and the production of reactive oxygen species by adipocytes, simultaneously increasing endogenous antioxidant transcription., In men and women with metabolic syndrome, supplementation of 150 mg of SPBE daily for 3 months significantly decreased waist circumference compared to placebo with reductions from 41.8 ± 0.9 inches to 38.9 ± 0.9 inches and 35.8 ± 0.6 inches to 33.3 ± 0.8 inches respectively.
Within the subset of health conditions that impact us with aging, the issues associated with metabolic syndrome (hyperglycemia, dyslipidemia, hypertension, and abdominal obesity) tend to infiltrate gradually. Although much of the management, particularly in the early stages of onset, is to follow a healthy diet and increase exercise, nutritional supplements may also help tip the scales back in one’s favor. SPBE is a supplement that can impact many of these issues at once, simultaneously providing strong free radical-scavenging activity, making it worthy of consideration.